deltatrials
Terminated PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT03474458

A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy

A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy

Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia

Conditions Cardiac AL Amyloidosis
Interventions Doxycycline Standard of care therapy
Updated 14 times since 2018 Last updated: Jul 10, 2024 Started: Feb 11, 2019 Primary completion: May 30, 2022 Completion: May 30, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

difficulty in recruitment

Other terminated trials from Fondazione IRCCS Policlinico San Matteo di Pavia

See all terminations from Fondazione IRCCS Policlinico San Matteo di Pavia

Listed as NCT03474458, this PHASE2/PHASE3 trial focuses on Cardiac AL Amyloidosis and remains terminated or withdrawn. Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia, it has been updated 14 times since 2019, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshot~Apr 2019 – ~Aug 2019 · 4 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Jan 2021 · 15 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jun 2022 · 16 months · monthly snapshot~Jun 2022 – ~Nov 2023 · 17 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2/PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2/PHASE3

  3. Aug 2024 — Sep 2024 [monthly]

    Terminated PHASE2/PHASE3

  4. Jul 2024 — Aug 2024 [monthly]

    Terminated PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  5. Nov 2023 — Jul 2024 [monthly]

    Terminated PHASE2_PHASE3

    Status: Active Not Recruiting → Terminated

▶ Show 9 earlier versions

  1. Jun 2022 — Nov 2023 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Recruiting → Active Not Recruiting

  2. Feb 2021 — Jun 2022 [monthly]

    Recruiting PHASE2_PHASE3

  3. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2_PHASE3

  4. Oct 2019 — Jan 2021 [monthly]

    Recruiting PHASE2_PHASE3

  5. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE2_PHASE3

  6. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2_PHASE3

  7. Apr 2019 — Aug 2019 [monthly]

    Recruiting PHASE2_PHASE3

    Status: Not Yet Recruiting → Recruiting

  8. Jun 2018 — Apr 2019 [monthly]

    Not Yet Recruiting PHASE2_PHASE3

  9. Apr 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2_PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fondazione IRCCS Policlinico San Matteo di Pavia
Data source: Fondazione IRCCS Policlinico San Matteo di Pavia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations